Futura’s Chairman, John Clarke, will make the following statement at the AGM.
“We continue to make good progress in the development and commercialisation of our pipeline of product opportunities.”
-This is just not true in terms of Pain Killers. There have been no reported successful negotiations, so Pain Killer development remains parked.
“The design of the (Phase III) study incorporates feedback from regulators and from potential commercial partners with whom the Company remains at an advanced stage of discussions. This feedback has, for example, highlighted the importance of the initial commercial target markets being men who are dissatisfied by the slow onset of action of PDE5 inhibitors or by side-effects and contraindications, such as those men with ED who are prescribed nitrates.”
- Its good that input from potential partners is being discussed / agreed. Discussions will maintain or increase potential partner interest / involvement, and assures that informed potential partners can see their priorities being taken into consideration. This might be the cause of the delay to Phase III doseing.
“Completion of a significant out-licensing agreement for MED2002 remains a top priority for the Company and, whilst negotiations proceed, we will continue to maintain the momentum in the product’s development.”
- Note agreement, not agreements.
“On our novel condom, CSD500, we are pleased to announce that the product has recently received regulatory approval in Kuwait, enabling our commercial partner in the MENA region to launch in Kuwait as soon as practicable. This follows the previous launch in the Kingdom of Saudi Arabia, from which repeat orders continue to be generated. In a number of other countries, the steps towards CSD500 launches are also underway. We continue in commercial discussions with potential partners for CSD500 for those territories where a commercial partner is not currently appointed.”
- Kuwait is good news, but only 4 million people (so 2 million men) live there.
- Still looking for partners for ex C&D territories. How hard are they looking with TTT a possibility?
"On TPR100, our diclofenac gel for topical pain relief, we await the UK regulatory dossier submission to the MHRA by Thornton & Ross, a UK subsidiary of STADA. The completion and submission of the dossier, which is substantial, remains a priority and we will provide a further update once the dossier has been filed.2
- Thornton & Ross are responsible for late submission? I hear what is being said, but I feel FUM may have its own timetable for submission that avoids problems for a TTT outcome.
- The dossier was one of the bigger problems JB had before he hired Angela.
“Futura has a strong balance sheet, an experienced team, an exciting product portfolio and a particularly valuable asset in MED2002, which has the potential to be the world’s fastest-acting ED treatment. We look forward to providing further updates in the current financial year.”
- Its official. MED2002 is now a ‘particularly valuable asset’, hence the employment of advisors. You get the feeling JB is getting an appetite for what the company is really worth, not just the Punchy Numbers.
From Wikipedia the following:
Kuwaiti Ethnic groups:
other Arab 27.9%
Asian(mostly south) 37.8%
other 1.1% (includes European, North American, South American, and Australian) (2013 est.)
I think a large part of the Saudi Arabian population is from similar sources?
This being the case, instead of just sending money home to families, the more entrepreneurial Arabs and Asians might start sending these super new condoms home to sell.
Possible or Probable do you think Aberdeen?